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Abstract. The -D-endoglycosidase heparanase has been pro-
posed to be important in the pathogenesis of proteinuria by
acting to selectively degrade the negatively charged side chains
of heparan sulfate proteoglycans (HSPG) within the glomerular
basement membrane (GBM). A loss of the negatively charged
HSPG may result in alteration of the permselective properties
of the GBM, loss of glomerular epithelial and endothelial cell
anchor points, and liberation of growth factors. This study
examined the effect of PI-88, a sulfated oligosaccharide
heparanase inhibitor, on renal function, glomerular ultrastruc-
ture, and proteinuria. Continuous PI-88 infusion at 25 mg/kg
per d did not adversely affect animal behavior, growth, or
GFR. Cortical tubular vacuolation, however, was observed by
light microscopy, and GBM thickness was significantly re-
duced in these animals (P  0.0002). Tissue distribution stud-
ies using [35S]-labeled PI-88 revealed high levels of radioac-
tivity in the kidney after a single subcutaneous injection of 25
mg/kg, suggesting protracted accumulation; moreover, active
PI-88 was detected in urine. In passive Heymann nephritis,
PI-88 delivered as a continuous infusion at 25 mg/kg per d
significantly reduced autologous-phase proteinuria, at day 14
(P  0.009), in the absence of altered sheep antibody deposi-
tion, C5b-9 deposition, and circulating rat anti-sheep antibody
titers. Glomerular vascular endothelial growth factor and fibro-
blast growth factor expression was unaffected by PI-88 admin-
istration. However, PI-88 administration significantly pre-
vented glomerular HSPG loss as demonstrated by quantitative
immunofluorescence studies (P  0.0001) in the absence of
altered agrin distribution. These data therefore confirm the
importance of heparanase in the development of proteinuria.
Alterations in the size and charge-dependent selectivity of the
glomerular basement membrane (GBM) have been described
in models of proteinuria (1–4). Heparan sulfate proteoglycans
(HSPG) that comprise a protein core covalently linked to
glycosaminoglycan side chains, such as heparan sulfate (HS),
are one of the most important constituents of the GBM (5). The
presence of sulfate and carboxyl groups in HS chains is re-
sponsible for the negative charge of the GBM at physiologic
pH. In human glomerulonephritis and experimental animal
models of proteinuria, loss of GBM charge has been demon-
strated using cationic stains; in addition, immunohistochemical
staining has suggested that charge loss is due to a reduction in
the number of negatively charged HS side chains (6–8).
Enzymatic digestion has been proposed to specifically de-
grade HS side chains, resulting in GBM charge loss (9,10).
Loss of HSPG integrity probably results in alterations to the
permselective properties of the GBM, disruption of the HSPG
anchor points that contribute to podocyte-GBM-endothelial
stability, and, finally, liberation of HSPG-bound growth fac-
tors, including fibroblast growth factor (FGF) (11), vascular
endothelial growth factor (VEGF) (12), and Heparin Binding
Epidermal Growth Factor-Like Growth Factor (HB-EGF) that
may affect podocyte function (13). The -D-endoglycosidase
heparanase has been proposed to be a candidate enzyme in-
volved in GBM HSPG degradation. We have previously shown
that heparanase expression is increased in experimental models
including puromycin aminonucleoside nephrosis (14), anti-
GBM disease (15), and passive Heymann nephritis (PHN) (16).
Endothelial and glomerular epithelial cells, which comprise the
cellular elements of the glomerular filtration barrier, produce
heparanase in response to injury. Subcellular localization stud-
ies have confirmed that the active 58-kD form of heparanase is
present in diseased glomeruli. Furthermore, we have demon-
strated increased heparanase activity in urine and glomeruli
derived from diseased animals with PHN, and administration
of an antiheparanase antibody reduced proteinuria at day 5 of
this model (16). More recently, studies of transgenic animals
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that overexpress heparanase have confirmed the importance of
heparanase in the development of proteinuria (17). Transgenic
animals develop significant spontaneous proteinuria associated
with renal impairment; ultrastructurally, abnormal podocyte
structure as defined by foot process effacement was observed.
In addition, active heparanase was identified only in transgenic
kidneys, suggesting that local rather than systemic heparanase
gives rise to proteinuria (17).
The important role that heparanase plays in malignancy and
in inflammatory models has been demonstrated by inhibition
studies (18–21). PI-88 is a mixture of highly sulfated synthetic
oligosaccharides that was primarily developed as an antitumor
agent. Inhibition of tumor heparanase activity is associated
with a reduction in tumor angiogenesis, growth, and metastasis
(22). PI-88 has a modest amount of anticoagulant activity,
inhibiting thrombin-induced platelet aggregation and prolong-
ing the activated partial thromboplastin time (APTT) in hu-
mans and animals (23). APTT prolongation has been shown to
correlate with PI-88 dosage in animals and is routinely used as
a surrogate marker of PI-88 absorption (23–25). It has success-
fully undergone Phase I trials in healthy volunteers and cancer
patients, demonstrating its low toxicity, and Phase II clinical
trials are currently in progress to evaluate the effect of PI-88 in
patients with malignancies. Furthermore, recent studies have
demonstrated that PI-88 directly binds to FGF-1, FGF-2, and
VEGF. In addition, FGF-2 binding by PI-88 renders it biolog-
ically inactive (26,27). PI-88 has been likened to a heparan
sulfate mimetic acting by simply sequestering released growth
factors and rendering them biologically inactive (28).
The present studies were designed to investigate the effect of
PI-88 administration on normal renal function and glomerular
ultrastructure. In addition, the effect of PI-88 on passive Hey-
mann nephritis, known to be associated with increased hepara-
nase expression, was examined.
Materials and Methods
Animal Studies
Progen Industries supplied the highly sulfated oligosaccharide PI-
88, which is predominately a sulfated pentasaccharide. PI-88 was
dissolved in sterile PBS (Life Technologies BRL, Gaithersburg, MD)
at 25 mg/kg per d and introduced into Alzet pumps (Alza Corp., Palo
Alto, CA) using a sterile technique, according to the manufacturer’s
instructions. Sprague Dawley rats that weighed 180 to 200 g were
anesthetized, a small midline abdominal incision was made, and
pumps were introduced exit port first into the abdominal cavity. The
resulting abdominal wall defect was repaired with Dexon IV suture
material, using a continuous-layer suture technique. The suture line
was treated with topical Betadine to minimize wound manipulation by
the animal and its littermates. All animals were placed in metabolic
cages at days 5, 10, and 14. Urine was collected for 24 h and analyzed
for proteinuria and hematuria. Urinary protein concentrations were
determined using the Bradford calorimetric method (Bio-Rad Labo-
ratories, Hercules, CA) according to the manufacturer’s instructions.
N-Multistix Reagent Strips for urinalysis were used to detect hema-
turia (Miles Australia Pty Ltd, Diagnostic Division, Mulgrave, Vic-
toria, Australia). Animals were weighed at days 0 and 14 and bled by
cardiac puncture at termination of the experiment. Serum and urine
creatinine levels were determined using a modified Jaffe reaction (29).
APTT and prothrombin time levels were determined using standard
hematologic assays. All experiments performed were approved by the
Animal Ethics Committee of Austin Health (Melbourne, Australia).
Light and Electron Microscopy
For light microscopy, kidney tissue was fixed in 4% paraformal-
dehyde. Sections were cut 4 m thick, dewaxed, stained using hema-
toxylin and eosin, and coverslipped using standard techniques. For
electron microscopy, sections were cut in 1.5-mm strips using a
scalpel and immersed in a solution of 20% glutaraldehyde in PBS (pH
7.2) for 2.5 h. Thereafter, sections were washed in PBS, embedded,
cut, and photographed.
Calculation of GBM thickness was performed using a calibrating
grid as a reference point. The “Videoprobe 32” (Leading Edge Pty
Ltd, South Australia, Australia) imaging computer program was used
to measure GBM thickness and generate values. A minimum of 200
measurements of GBM thickness were made for each experimental
animal.
Synthesis, Administration, and Determination of Tissue
Distribution of [35S]-Labeled PI-88
[35S]-labeled PI-88 was produced by incorporating [35S] sulfur
trioxide-pyridine complex (1 mCi/mg) with the oligosaccharide phos-
phate fraction isolated from Pichia holsti (30). The purity of the end
product was identified using capillary electrophoresis (31). Fifteen
male Sprague Dawley rats that weighed 279 to 328 g at the time of
dosing were used. Animals were placed in cages with raised mesh
floors to prevent coprophagy. Water and food were offered ad libitum.
[35S]-labeled PI-88 was administered in the interscapular region as a
single 25-mg/kg subcutaneous dose. Animals were killed at 1, 4, 12,
24, and 168 h after dosing (n 3 per time point). Blood was collected
before the animals were killed, and aliquots were made up to 1 ml in
distilled water and mixed with 10 ml of Quickszint 1 scintillation
fluid. Samples were analyzed for 5 min using blanks and standards
concurrently. A background count was calculated and subtracted from
each sample count. The remaining carcass was immersed in a mixture
of solid CO2 and hexane for 30 min, embedded in methylcellulose,
and frozen in the same mixture.
Sagittal sections, 30 m thick, were cut at three levels, three
sections per level, using a whole-body cryomicrotome (Leica Instru-
ments). Sections were freeze-dried and exposed to phosphor image
plates for 7 d. Standards of blood spiked with known radioactive
concentrations were included in each instance. After 7 d, the phosphor
screens were analyzed using a Packard Cyclone (Packard Biosciences
Limited, Pangbourne, UK), and the stored energy was scanned and
saved digitally. Radioactivity was quantified using the standards as
reference points. The signal response for each standard was compared
with the true d.p.m.g1 for the range of radioactive concentrations
used, and a regression equation was derived for each standard.
Urinary Recovery of [35S]-Labeled PI-88
Metabolism of PI-88 was investigated by HPLC-radiochromato-
gram studies of urine collected 12 h after administration of either
intravenous or subcutaneous [35S]-labeled PI-88 at 25 mg/kg. For
HPLC-radiochromatogram analysis, 10 l of urine was run on a
Tosohaas TSK-Gel G2500WXL 6 (300  7.8 mm) column. All
fractions were collected manually, and radioactivity was measured
using liquid scintillation counting as described previously.
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Induction of PHN
Male Sprague Dawley rats that weighed 180 to 200 g were used,
and anti-Fx1A sheep serum was injected intravenously to induce PHN
as described previously (16). Twenty-four hours before disease in-
duction, Alzet osmotic pumps were inserted as outlined above; ex-
perimental intervention animals received a PBS-based solution of
PI-88 at 25/mg/kg (n  7), whereas control experimental animals (n
 7) received pumps that were preloaded with PBS. Animals were
housed in metabolic cages for 24 h, and urine was collected at days 5,
7, 10, and 14. Animals were killed using a lethal dose of intraperito-
neal phenobarbitone 14 d after disease induction. Tissue was har-
vested and fixed, and blood was collected for APTT/prothrombin time
estimation. Urinary protein concentrations were quantified using the
Bradford calorimetric method (Bio-Rad Laboratories). Urine was tested
for hematuria using dipstick analysis. Serum and urine creatinine levels
and coagulation studies were performed as described above.
Detection of Anti-Sheep Antibodies by ELISA
ELISA was performed as described by Engvall and Perlman (32).
A solution of PBS/Triton X was used for all washing steps. Briefly, 10
g of sheep IgG (Sigma, St. Louis, MO) was diluted in carbonate
bicarbonate buffer (15 mM Na2CO3; 35 mM NaHCO3 [pH adjusted to
9.5], made up to 1 L with milliQ [MQ]). ELISA plates (Dynatech
Laboratories Ltd, Chantilly, VA) were coated with 100 l of sheep
IgG solution and incubated overnight at 4°C. Plates were washed three
times, and 2% BSA in PBS was used to block nonspecific binding.
Plates were incubated at 37°C for 1 h. Once again, plates were washed
three times, and rat serum was diluted in 2% BSA at 1:100, 1:200,
1:400, and 1:800. Plates were incubated at room temperature for 1 h.
Plates were washed twice. Rabbit anti-rat HRP antibody at 1:5000
(DAKO) was diluted in 2% BSA, and 100 l was added per well and
incubated for 1 h. Wells were washed three times and developed using
o-phenylenediamine (DAKO) according to the manufacturer’s in-
structions. ELISA plates were read at an OD of 490 nm using an
ELISA plate reader (Behring EL 311 Microplate Reader, Behring-
werke, Germany). The averaged preimmune serum OD reading was
used as a reference to determine the end dilution of the experimental
serum reactivity with fixed sheep IgG.
Immunofluorescence Studies
Fresh tissue for immunofluorescence studies was embedded in
OCT compound (Lab-Tek Products, Miles Laboratories, Naperville,
IL) and snap-frozen in liquid nitrogen. Sections were cut 4 m thick
using a cryostat, air-dried, and stored at 70°C until required. Tissue
was fixed in methanol at 4°C for 20 min and blocked in 20% rat serum
for 60 min. Rat sheep IgG was detected using biotinylated anti-sheep
Ig (Amersham Pharmacia Biotech UK Limited) at 1:100. FITC-
Streptavidin was used to detect fixed biotinylated antibody, at 1:100
for 30 min; sections were then washed and mounted. Rat C5b-9 was
detected using biotinylated anti-rat C5b-9 monoclonal antibody 2A1
(33). HSPG staining was performed using the mouse monoclonal
antibody JM-403 at a dilution of 1:200. JM-403 is directed against the
low sulfated domains of HS containing an N-unsubstituted glu-
cosamine unit (34). Sections were fixed in acetone at 4°C for 10 min,
washed in PBS, and then blocked in 1% BSA 10% rat serum for 20
min. Thereafter, antibody at 1:200 in blocking buffer was incubated
on sections for 2 h in a humidified chamber at room temperature.
Sections were then washed and incubated with goat anti-mouse Ig
conjugated with Texas red (Pharmingen BD Biosciences Canada) at a
dilution of 1:150 for 30 min. Thereafter, sections were washed; fixed
in 1% paraformaldehyde for 15 min; washed in PBS; and finally
mounted, coverslipped, and examined using fluorescence microscopy.
PI-88 and N/saline-treated rat kidney sections were used as positive
controls. Staining intensity was similar in these two controls, con-
firming that JM-403 does not nonspecifically bind to PI-88. In addi-
tion, the glomerular staining intensity of controls was greater when
compared with the PHN experimental animal groups. The hamster
polyclonal MI-91 directed against the N-terminal half of rat agrin was
used to determine whether the agrin content of glomeruli remained
unchanged as described previously (35). The Scion Image Release
Beta 3b (National Institutes of Health, Bethesda, MD) image analysis
software package was used to quantify immunofluorescence-staining
loss. A total of 40 glomeruli were imaged from sections derived from
several animals in each experimental group. All images were captured
using the Leica DC Viewer Digital Imaging Systems software pack-
age, using identical settings for exposure time and gain.
Figure 1. Effect of PI-88 treatment on the light microscopic appear-
ance of normal kidney. Normal kidney cortex (A) and the appearance
of PI-88–treated cortex (B) are shown. Marked tubular vacuolar
changes were seen after PI-88 treatment (C and D), marked by arrows.
Magnification: 20 in A through C; 40 in D.
Table 1. GFR, animal weight, and APTT changes 14 days post-PI-88 administration
Day 0 Day 14 P Value
Calculated GFR (ml/min per kg) 0.0052 0.001 0.0049 0.001 NS
Animal weight (g) 188 2.7 274 2.7 0.002 (Mann Whitney)
APTT (s) 15 1.5 32 5.2 0.003 (Mann Whitney)
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FGF and VEGF Staining Studies
For determining expression of FGF-2 and VEGF, 4% paraformal-
dehyde-fixed sections were dewaxed, treated with 3% H2O2 in meth-
anol to remove endogenous peroxidases, and blocked with CAS block
(Zymed Laboratories, South San Francisco, CA) for 60 min. Anti–
FGF-2 antibody (Chemicon International, Temecula, CA), diluted
1:100, was incubated on sections overnight at 4°C. Rabbit IgG
(DAKO) was used as a negative control. Antibody binding was detected
using the DAKO LSAB kit according to the manufacturers’ instructions.
Sections were developed with diaminobenzidine, counterstained, and
coverslipped. VEGF expression was detected using a validated rabbit
polyclonal antibody at 1:300 as described previously (36)
Figure 2. Effect of PI-88 treatment
on glomerular basement membrane
(GBM) thickness. PI-88–treated an-
imals have a thin but normal GBM
(A and B) compared with control
animals (C and D). Normal podo-
cytes and endothelial cells abut the
GBM in both groups (denoted by *).
Magnification, 15,120.
Table 2. Tissue concentrations of [35S]-PI-88 post-subcutaneous administration at 25 mg/mg
Tissue 1 Hour 4 Hours 12 Hours 24 Hours 168 Hours
Blood 25.05 7.09 0.37 0.22 0.31
Kidney cortex 65.34 92.28 135.34 177.75 143.05
Kidney medulla 35.31 22.01 4.93 3.59 17.59
Kidney, whole 53.03 73.90 106.36 135.34 98.40
Periosteum 113.75 153.82 109.10 117.01 76.03
Spleen 10.02 10.94 10.48 11.69 11.20
Skin 29.43 21.17 14.28 14.19 10.30
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Results
Effect of PI-88 Administration in Normal Rats
PI-88, administered for 14 d as a continuous intraperitoneal
infusion, did not affect animal behavior or eating habits. The
average weight at day 14 after treatment was 274  2.7 g,
compared with 188  2.7 g at baseline (P  0.0001, paired t
test; n  5; Table 1). Urine samples from days 5, 10, and 14
after commencement of PI-88 contained neither protein nor
blood. Calculated GFR were no different before PI-88 admin-
istration or 14 d later (P  0.8015, paired t test; Table 1). As
an internal control, APTT estimations were found to be
significantly increased in the PI-88 –treated animals, com-
pared with normal rats, confirming PI-88 absorption (Table
1). Macroscopically, kidneys from rats that were treated
with PI-88 were edematous at the time of harvest. Light and
electron microscopy revealed normal podocyte and endothe-
lial ultrastructure and marked tubular vacuolation (Figure 1). The
GBM thickness, however, was significantly reduced (P 0.0002,
unpaired t test) in the PI-88–treated animals in contrast to the
normal rat GBM when examined by electron microscopy. The
average GBM thickness after PI-88 treatment for 14 d, in two of
the rats, was 101.95  16.2 and 114.3  22.9 nm. In contrast,
GBM thickness in two normal rats was calculated to be 123 9.8
and 121  11.7 nm (Figure 2).
[35S]-Labeled PI-88 Tissue Distribution Study
Tissue distribution studies were performed to investigate the
half-life of PI-88 and to establish whether it is accumulated in
Figure 3. Autoradiograms of sections through a male Sprague Dawley
rat 12 h after a single 25-mg/kg subcutaneous dose of [35S] PI-88. (A
through C) Sections through three levels; note the marked signal
intensity from the kidney and periosteum. (D) Magnification of bone
12 h after PI-88 administration. Note the marked periosteal signal. B,
bone; BF, brown fat; BM, bone marrow; Br, brain; E, eye; H, heart;
I, intestine; K, kidney; LG, lacrimal gland; L, lung; Lv, liver; M,
muscle; P, periosteum; Pi, pituitary gland; R, rectum; S, stomach; T,
testes; TG, thyroid; TH, thymus; WF, white fat.
Figure 4. Autoradiograms of sections through kidney after administra-
tion of a single 25-mg/kg subcutaneous dose of [35S] PI-88. Magnifica-
tion of the kidney at 1, 4, 12, and 168 h after administration of [35S]
PI-88. Note the marked cortical pooling and relative sparing of the
medulla in the kidney. KC, kidney cortex; KM, kidney medulla; U, urine.
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the cortex of the kidney, the site of its proposed action. A
single 25-mg/kg [35S] PI-88 dose was associated with perios-
teum tissue concentrations of 113.75 and 153.82 g equiv/g at
1 and 4 h, respectively (Table 2). In contrast, kidney cortex
contained 64.54 and 92.28 g equiv/g at these time points.
Thereafter, PI-88 was predominantly concentrated in the kid-
ney cortex, reaching a peak of 177.75 g equiv/g at 24 h. A
17-fold higher concentration was noted in kidney cortex com-
pared with the amount found in spleen at 24 h (Table 2).
Accumulation of [35S] radioactivity in the periosteum and
kidneys 12 h after administration of [35S] PI-88 is illustrated by
representative whole-body autoradiographs (Figure 3, A
through C) and in magnified sections of bone (Figure 3D) and
kidneys (Figure 4). Tissue concentrations of [35S] radioactivity
remained high for up to 168 h after PI-88 administration. In
contrast, blood levels of PI-88 rapidly diminished after 1 h,
confirming a plasma half-life of 2 h. HPLC-radiochromato-
gram analysis of urine samples after administration of 25
mg/kg PI-88 confirmed that the majority of urinary radioac-
tivity co-eluted with authentic PI-88 (Figure 5). Of note, no
increase in radioactivity associated with free 35S-sulfate was
detected, indicating metabolic stability of the radiolabeled
drug.
Effect of PI-88 on PHN
Animals were pretreated for 24 h before disease induction
with a continuous PI-88 infusion of 25 mg/kg per d. There
were no bleeding complications associated with this regimen.
Animals gained weight equally in both experimental groups
(Figure 6A). The terminal APPT levels confirmed systemic
absorption of PI-88 (P  0.0001, unpaired two-tailed t test;
Figure 6B). A direct comparison of weight versus PI-88 dose
was made. Animals received 25 mg/kg per d at disease induc-
tion, whereas by day 14, because of their weight gain, only 17
mg/kg per d PI-88 was being administered (Figure 7A).
Although the amount of protein excreted at days 5, 7, and 10
of disease was not significantly different in the two groups,
proteinuria at day 14 of disease was 437  144.8 in PI-88–
treated animals compared with 725.7  207.4 g/d in experi-
mental control animals (P 0.009, Mann-Whitney test; Figure
7B). The light microscopic appearances of glomeruli at day 14
of disease in PI-88–treated animals and control experimental
animals were similar (Figure 8, A and B, respectively); how-
Figure 5. HPLC-radiochromatogram studies of urine after PI-88 ad-
ministration. Recovered urinary radioactive PI-88 HPLC profiles after
intravenous (A) and subcutaneous (B) PI-88 administration. The iden-
tified peak represents the PI-88 fraction (labeled PI-88), “degraded”
PI-88 is marked by an arrow and labeled “SO4.” (Results are ex-
pressed as dpm in each fraction as a percentage of the total radioac-
tivity recovered from the column. Elution times of authentic PI-88 and
sulfate shown by arrows).
Figure 6. Effect of PI-88 on animal weight and activated partial
thromboplastin time (APTT). (A) Effect of PI-88 treatment on weight
gain. There was no statistically significant disparity in weight gain in
the two experimental groups, at day 14 of disease. (B) APTT mea-
surements. At day 14 of disease, the PI-88–treated group had a
statistically significant prolongation in APTT compared with N/saline
controls (P  0.0001, unpaired two-tailed t test). PI-88–treated ani-
mal group, 31.12  5.19; sham group, 16.16  2.04 s.
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ever, tubular vacuoles were noted in PI-88–treated animals
compared with experimental control animals (Figure 8, C and
D, respectively).
For determining whether PI-88 had an immunomodulating
effect, rat anti-sheep antibody titers were quantified and found
to be unaffected by PI-88 treatment (6171  3508), compared
with control experimental animals (4200  3818). Similarly,
sheep IgG (Figure 9, A and B) and C5b-9 (Figure 9, C and D)
deposition was unaltered by PI-88. HSPG glomerular content
as shown by immunofluorescence staining was preserved to a
greater extent in the PI-88–treated experimental animals (Fig-
ure 10C), in the absence of altered agrin composition in either
group (Figure 10, A and B). Fluorescence intensity loss for
HSPG, when quantified, was significantly greater in the N/sa-
line-treated animals when compared with the PI-88–treated
experimental animal group (P  0.0001, unpaired t test with
Welch correction; Figure 10E). VEGF and FGF staining inten-
sity were investigated in the intervention and experimental
animal group. No difference in staining intensity for either
growth factor was observed at day 14 (data not shown). Ultra-
structural comparison of GBM thickness was not possible
given the presence of immune deposits and the associated
basement membrane thickening characteristic of PHN. There
was, however, no apparent change by electron microscopy.
Discussion
After 14 d of intraperitoneal infusion, the heparanase inhib-
itor PI-88 seems to have caused no adverse effect on weight
gain, creatinine clearance, or animal behavior. The APTT was
prolonged, confirming systemic absorption. Glomeruli, as
shown by light microscopy, seemed unaltered. However, the
electron microscopic finding of a thin GBM in the presence of
normal glomerular epithelial and endothelial cells, in the ab-
sence of hematuria and proteinuria, is of considerable interest.
Thinning of the basement membrane was “patchy,” the distri-
bution pattern mimicking that seen in thin basement membrane
disease (TBMD) in man.
TBMD, in humans at least, has been considered an anatomic
variation of GBM thickness whereby the glomerular epithelial
and endothelial cells remain normal in ultrastructure. Linkage
analysis studies, however, have recently shown that nearly half
of these patients’ family members have segregation of hema-
turia at the COLA3/A4 locus (36%) or the COLA5 locus (10%),
the same loci for autosomal recessive and X-linked Alport
syndrome, respectively (37,38). These data suggest that 50% of
patients who have a diagnosis of TBMD actually have Alport
syndrome, but the cause of the GBM abnormality in the re-
maining cases has, as yet, not been determined.
In these animal studies, normal GBM width seems to be
reliant on heparanase activity, as heparanase inhibition using
PI-88 resulted in the development of a thin GBM. The exact
Figure 7. Effect of PI-88 on protein excretion. (A) Weight compared
with PI-88 dose. Animals at disease induction received 25 mg/kg per
d PI-88; by day 14, because of weight gain, 17 mg/kg per d was being
infused. (B) Proteinuria was significantly reduced in the PI-88–treated
group at day 14 of disease, compared with N/saline-treated controls (P
 0.009, Mann-Whitney test). At day 14 of disease, PI-88–treated
animals excreted 437  144.8 versus 725.7  207.4 g/d of protein.
Mean and SD shown.
Figure 8. Light microscopic appearance of PI-88 kidneys from PI-
88–treated animals with passive Heymann nephritis. N/saline-treated
diseased animals had normal glomeruli (A) and tubules (C). In con-
trast, PI-88–treated experimental animals had normal glomeruli (B)
and contained tubules that demonstrated marked vacuolar changes
(D), marked by arrows. Magnification, 40.
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mechanism responsible for this observation can only be spec-
ulated. Possible explanations include (1) a reduction in the
amount of HSPG-bound growth factors liberated that are re-
quired to maintain normal GBM integrity, (2) a reduction in the
amount of HSPG produced that contribute to adhesion of the
GBM components, and (3) a reduction of the synthesis of
GBM components by cells that compose the filtration barrier.
At present, it is not clear which of these possibilities could
account for this observation. It is known that FGF is abundant
in the GBM (39) and that PI-88 directly binds to FGF and
renders it biologically inactive (27). This known effect of PI-88
may contribute to abnormal GBM biosynthesis.
The tubules of the cortex and medulla, 14 d after PI-88
administration, contained clear cytoplasmic vacuoles on exam-
ination by light microscopy. Despite these changes, the creat-
inine clearance was unaltered, suggesting that glomerular func-
tion was unaffected. The cause and composition of these
vacuoles are unknown. Vacuolation is often associated with
lipid deposition and cellular edema. It is possible that PI-88
might be internalized and stored in these cells after binding to
cell membrane associated heparanase. Recent studies have
suggested that heparanase is primarily localized within lyso-
somes and the Golgi, where lysosomal containment is believed
to prevent uncontrolled heparanase activity (40). It is possible
that PI-88 may affect normal Golgi or tubular lysosomal turn-
over. Administration of suramin, a polysulfonated napthylurea
and known inhibitor of heparanase, is associated with the
formation of lysosomal accumulations and lamellar inclusions
in kidney tubular cells (37,38). The renal toxicity of suramin
has limited its clinical usage (41), and the induced lysosomal
changes make it an ideal agent to study lysosomal storage
diseases (37,42). It is possible, therefore, that PI-88, like
suramin, disturbs the same biochemical pathways to produce
these changes. Unlike suramin, no abnormal spleen or liver
abnormalities have been noted after PI-88 administration.
The pharmacodynamics of accumulated PI-88–derived ma-
terial in the kidney has not been established; however, PI-88
excreted in the urine seems to be intact as shown by HPLC
radiochromatogram studies 12 h after intravenous and subcu-
taneous PI-88 administration. Peak levels of [35S] radioactivity
after a single 25-mg/kg dose of [35S]-PI-88 were determined at
4 h in the periosteum and 24 h in the kidney cortex by
quantitative whole-body autoradiography. Total radioactivity
in these tissues remained significantly elevated for up to 168 h,
the final time point of these studies. The kidneys, therefore,
accumulate PI-88–related material. Peak radioactivity corre-
lated with cortical tubular cell vacuolation, suggesting that
PI-88 or its metabolites accumulate in these vacuoles. Radio-
activity in bone marrow, liver, cervical lymph nodes, and
spleen may represent macrophage-associated uptake of PI-88
or its metabolites.
PI-88 administration significantly reduced the amount of
Figure 9. Sheep IgG and C5b-9 im-
munofluorescence studies. Sheep
IgG deposition was unaltered by
PI-88 treatment (B) when compared
with N/saline-treated diseased ani-
mals (A). Similarly, C5b-9 activity
was unaffected by PI-88 (D) com-
pared with the N/saline experimental
group (C). Magnification, 40.
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proteinuria at day 14 of disease during the autologous phase of
PHN. This model of glomerulonephritis is characterized by
focal GBM thickening and immune deposits. The patchy na-
ture of GBM thickening (43) made GBM width calculations
unreliable. The finding of similar rat anti-sheep antibody titers,
sheep IgG deposition, and C5b-9 activity in the two groups, at
day 14, suggests that PI-88 was not acting as an immunosup-
pressant and did not prevent the development of the PHN
model.
Raats et al. (9,10) demonstrated HSPG loss in several mod-
els of glomerulonephritis, including PHN. Endoglycosidase
activity was predicted at the time to contribute to HSPG
degradation. PI-88 administration not only reduced proteinuria
at day 14 in PHN but also significantly preserved glomerular
HSPG content as shown by immunofluorescence quantification
studies while the agrin composition of glomeruli was main-
tained. This finding confirms that heparanase activity is asso-
ciated with GBM breakdown via HSPG degradation. Protein-
Figure 10. Heparan sulfate proteo-
glycan (HSPG) quantification stud-
ies. PI-88– and N/saline-treated ex-
perimental animals contained
similar amounts of agrin in their glo-
meruli (A and B, respectively). In
contrast, glomeruli from PI-88–
treated experimental animals con-
tained significantly more HSPG as
compared with N/saline-treated ex-
perimental animals (C and 10, re-
spectively). This observation was
confirmed using immunofluores-
cence quantification studies (P 
0.0001, unpaired t test; E). Fluores-
cence intensity loss in PI-88–treated
animals was 151.03 20.84; in con-
trast, in N/saline-treated experimen-
tal animals, fluorescence intensity
loss was 233.41  22.37, mean and
SD shown. Magnification, 400.
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uria was not prevented in this model, suggesting that
heparanase only partially contributes to proteinuria. Further-
more, PI-88 binds and inactivates FGF (27). Podocytes have
been shown to release FGF in response to injury in PHN, and
FGF administration augments podocyte injury (11). PI-88,
therefore, could also modify disease progression through inhi-
bition of FGF activity. The observation that PI-88 treatment
does not diminish local FGF or VEGF is consistent with its
confirmed mechanism of action as a mimetic of HSPG. The-
oretically, PI-88 could reduce the amount of “biologically
active FGF and VEGF”; however, the actual content might
remain unchanged. Clearly, immunohistochemistry cannot dis-
tinguish between inactive and active growth factors. In this
model, at least at day 14 of disease, heparanase inhibition
apparently did not diminish the amount of glomerular VEGF or
FGF, suggesting that heparanase activity does not solely con-
tribute to release of these growth factors from HSPG.
Recent evidence for heparanase overexpression in transgenic
animal studies has confirmed the importance of this endogly-
cosidase in the pathogenesis of proteinuria. Progressive renal
failure was also noted in these animals and could be linked to
unchecked growth factor liberation (11), although we did not
find the converse when heparanase was inhibited with PI-88.
In conclusion, this study demonstrates that PI-88 has no
adverse effect on glomerular function in normal animals but
gives rise to a “thin” GBM in the absence of hematuria and
proteinuria. This is the first description of the development of
an abnormal basement membrane as a consequence of admin-
istration of a pharmaceutical. Whether reduced activity of
heparanase contributes to abnormal GBM thickness or
TBMD in humans has yet to be determined. PI-88 admin-
istration reduced proteinuria in a model of PHN without
modulating the immune system. PI-88 administration was
associated with preservation of the HSPG content in glo-
meruli, confirming the importance of heparanase in the
development of proteinuria.
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